Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Business Ethics
Contact us
Product pipeline
ELND005
Anti-inflammation
Anti-diabetes compounds
Current partnership
In/Out-licensing opportunity
ELND005 Phase II
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2011
Press release archive
Webcast and presentation
INVESTOR relations
Stock Quotes
Financial Reports
Analyst Coverage
Request Information
E-mail Alert
SEDAR filings
EDGAR filings
Annual Reports
2011
2010
2009
2008
Financial Reports
Fiscal Year
First Quarter
Second Quarter
Third Quarter
Year-End
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
Auditor
PricewaterhouseCoopers LLP
Mississauga, Ontario, Canada
© 2011 Transition Therapeutics Inc.
